Denali Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value
Denali Therapeutics Inc. (DNLI) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value of $10.66 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue · last filed 2026-02-26
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value $10.66M.
- 2024-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value $32.31M.
- 2023-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value $45.15M.
- 2022-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value $84.71M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value |
|---|---|
| 2025-12-31 | $10.66M 10-K · filed 2026-02-26 |
| 2024-12-31 | $32.31M 10-K · filed 2025-02-27 |
| 2023-12-31 | $45.15M 10-K · filed 2024-02-28 |
| 2022-12-31 | $84.71M 10-K · filed 2023-02-27 |
| 2021-12-31 | $256.78M 10-K · filed 2022-02-28 |
| 2020-12-31 | $717.29M 10-K · filed 2021-02-26 |
| 2020-03-31 | $35.13M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $22.67M 10-K · filed 2020-02-27 |
| 2019-09-30 | $2.38M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $61.40M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $92.15M 10-Q · filed 2019-05-08 |
| 2018-12-31 | $62.94M 10-K · filed 2019-03-12 |
| 2018-09-30 | $73.66M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $25.34M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $62.62M 10-Q · filed 2018-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |